HER2 gene and protein expression status of breast carcinoma can be reliably tested on a single slide (Q35929360)

11 August 2017

HER2 gene and protein expression status of breast carcinoma can be reliably tested on a single slide (English)

1 reference

11 August 2017

1 reference

Marie-Pierre Chenard

1

1 reference

11 August 2017

Marie-Pierre Wissler

2

1 reference

11 August 2017

Noëlle Weingertner

3

1 reference

11 August 2017

Carole Mathelin

4

1 reference

11 August 2017

Jean-Pierre Bellocq

5

1 reference

11 August 2017

19 May 2015

1 reference

11 August 2017

1 reference

11 August 2017

467

1 reference

11 August 2017

2

1 reference

11 August 2017

169-175

1 reference

Creative Commons Attribution 4.0 International

11 August 2017

start time

19 May 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4529453

A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4529453

Treatment of HER2-positive breast cancer: current status and future perspectives.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4529453

Clinical and health economic outcomes of alternative HER2 test strategies for guiding adjuvant trastuzumab therapy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4529453

Emerging technologies for assessing HER2 amplification

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4529453

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4529453

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4529453

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4529453

HER-2/neu (c-erbB-2) evaluation in primary breast carcinoma by fluorescent in situ hybridization and immunohistochemistry with special focus on intratumor heterogeneity and comparison of invasive and in situ components

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4529453

Marked intratumoral heterogeneity of c-myc and cyclinD1 but not of c-erbB2 amplification in breast cancer.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4529453

Untangling the ErbB signalling network

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4529453

Role of HER2 gene overexpression in breast carcinoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4529453

Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4529453

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4529453

Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4529453

Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4529453

Genetic heterogeneity in HER2 testing may influence therapy eligibility.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4529453

Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4529453

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

24 September 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4529453

24 September 2018

https://api.crossref.org/works/10.1007%2FS00428-015-1781-0

Simultaneous analysis of HER2 gene and protein on a single slide facilitates HER2 testing of breast and gastric carcinomas

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25985875

12 December 2020

inferred from PubMed ID database lookup

HER2 gene amplification in patients with breast cancer with equivocal IHC results

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25985875

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1007/S00428-015-1781-0

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/blekurlmirgtxmfut4yvzweyzu

30 July 2022

release_blekurlmirgtxmfut4yvzweyzu

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/blekurlmirgtxmfut4yvzweyzu

30 July 2022

https://api.fatcat.wiki/v0/release/blekurlmirgtxmfut4yvzweyzu

1 reference

30 July 2022

https://api.fatcat.wiki/v0/release/blekurlmirgtxmfut4yvzweyzu

PubMed publication ID

1 reference

30 July 2022